Filing Flows › Arrowhead Pharmaceuticals (ARWR) › Q4 FY25
Arrowhead Pharmaceuticals (ARWR) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Nov 25, 2025
Arrowhead Pharmaceuticals (ARWR) reported revenue of $256M for the fourth quarter fiscal 2025 (Q4 FY25) and +824% from the quarter before. Operating margin was 17.2%, net earnings $16.1M (6.3% of revenue).
Arrowhead Pharmaceuticals, Q4 FY25: revenue $256M, operating margin 17.2%, net earnings $16.1M, operating cash flow $20.5M. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $256M | +824% | — |
| Operating profit | $44.1M | — | — |
| Net earnings | $16.1M | — | — |
| Operating cash flow | $20.5M | — | — |
| Free cash flow | $13.0M | — | — |
What changed
Revenue was $256.5M in Q4 FY25, up 824% from the previous quarter.
Operating profit was $44.1M, a 17.2% margin. Net earnings were −$23.8M. The effective tax rate was 55.4%.
Operating cash flow was $20.5M, 127% of net income including minority interests. Non-cash charges added back $6.0M of depreciation and amortization and $19.1M of share-based compensation. Working capital and other items used $20.7M. Capital expenditures of $7.5M left free cash flow of $13.0M.
Questions
What was Arrowhead Pharmaceuticals' revenue in the fourth quarter fiscal 2025?
Arrowhead Pharmaceuticals (ARWR) reported revenue of $256M for the fourth quarter fiscal 2025 (Q4 FY25) and +824% from the quarter before.
Was Arrowhead Pharmaceuticals profitable in the fourth quarter fiscal 2025?
Operating profit was $44.1M (17.2% of revenue) and net earnings $16.1M.